The "Jikeshu Innovative Anti-Influenza Drug: 1-Dose Launch Event" — a key component of the forum — drew widespread attention from attendees. Jikeshu (Sebaloxavir Marboxil Tablets) is a new-generation targeted inhibitor of influenza virus RNA polymerase PA. Clinical studies show that Jikeshu has a long half-life and high plasma exposure, supporting a single-dose, full-course treatment regimen with no need for weight-based dose adjustment, making administration more convenient and providing lasting health protection. After administration, peak plasma concentration is reached within 3 hours, enabling rapid onset of action, fever reduction within 1 day, significant improvement of all influenza symptoms within 39.4 hours, rapid viral clearance, and shortened disease course. The incidence of adverse events is low; the drug is primarily metabolized via non-CYP enzyme pathways, resulting in a low risk of drug interactions. The "single oral dose, full-course efficacy" dosing regimen is expected to provide influenza patients with the experience of "one dose for lasting relief, fever resolved in one day, and peace of mind in use."